Akero logo with white space 1.jpg
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 16:05 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment
November 12, 2021 08:01 ET | Akero Therapeutics
Most EFX-treated patients with end-of-treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks Histological...
Akero logo with white space 1.jpg
Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021 07:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero logo with white space 1.jpg
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
November 09, 2021 16:15 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
October 19, 2021 16:15 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...
Akero logo with white space 1.jpg
Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference
October 05, 2021 08:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero logo with white space 1.jpg
Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference
September 07, 2021 08:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero logo with white space 1.jpg
Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021 07:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero logo with white space 1.jpg
Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors
July 14, 2021 08:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero logo with white space 1.jpg
Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment
July 08, 2021 11:10 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...